Signaling pathways
-
BA1814 SelgantolimodSummary: Selgantolimod (GS-9688) is orally active. - BA1818 BicyclolSummary: Bicyclol (SY801) is an orally available anti-HBV.
- BA1824 VonafexorSummary: Vonafexor (EYP001) is an orally active and selective nonsteroidal agonist.
- BA1833 AT-130Summary: AT-130, a phenylacrylamide derivative, is a potent non-nucleoside inhibitor of hepatitis B virus replication.
- BA1834 ElebsiranSummary: An siRNA against hepatitis B virus and hepatitis D virus (HDV) infection.
- BA1837 HBV-IN-4Summary: HBV-IN-4, a phthalazinone derivative, is a potent replication inhibitor with oral activity.
- BA1845 RO6889678Summary: RO6889678 is a potent inhibitor of the coat structure with a complex absorption, distribution, metabolism and excretion (ADME) profile.
- BA1852 NIM811Summary: NIM811 ((Melle-4)cyclosporin; SDZNIM811) is an orally active dual inhibitor of mitochondrial osmotic transition and procyclosporin.
- BA1855 AlisporivirSummary: Alisporivir (Debio-025) is a procyclin inhibitor.
- BA1858 GSK-A1Summary: GSK-A1 is a selective type III phosphatidylinositol 4-kinase PI4KA inhibitor.